Alvotech signs U.S. agreement to expand access for high-concentration interchangeable Humira biosimilar

Alvotech announced a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly Food and Drug Administration approved high-concentration interchangeable biosimilar to Humira.

“This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient access to more affordable healthcare,” said Robert Wessman, chairman and CEO of Alvotech.

[Read more: Alvotech, Teva obtain FDA OK for Humira biosimilar]

The current multi-product commercialization partnership between Teva and Alvotech remains unchanged and Teva will continue to commercialize adalimumab-ryvk under the Simlandi brand in the United States.

[Read more: Teva rolls out generic Nexavar tablets]